Mahboob Vaseem sold $418K of KMTS

Mahboob Vaseem (Chief Financial Officer) sold 18,188 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $22.99 ($22.61–$23.80, $0.42M total) across 3 trades over 2026-07-30 to 2026-08-03.

Original reporting
SEC EDGAR · Mahboob Vaseem
Published Aug 3, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The only disclosed new fact is the CFO’s open-market sale details and post-transaction holdings; there is no accompanying corporate event or performance update.

02

Market read

Traders may briefly reassess sentiment around KMTS due to insider selling, but the filing lacks fundamental catalysts.

03

What to watch

The filing does not state motivations, and the sale window spans multiple days with a modest post-sale holding count; traders should avoid extrapolating company deterioration from one transaction.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-03 after-hours; reflects trades dated 2026-07-30 to 2026-08-03

Background

The article is a SEC Form 4 insider transaction for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) by its CFO.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

KMTS CFO Mahboob Vaseem sold $418,217 of KMTS shares in open-market trades from 2026-07-30 to 2026-08-03.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-on insider activity or company-specific catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction, but it does not include new company performance, guidance, or deal information. The absence of a stated 10b5-1 plan can raise scrutiny, yet the disclosed size is not clearly market-moving on its own.

Market effects

Minimal; insider selling in a single medical technology name does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; without additional context, the signal may be overstated.

Key entities

  • KMTS

    Kestra Medical Technologies, Ltd., the company whose insider transaction was filed.

  • Mahboob Vaseem

    Chief Financial Officer of KMTS who sold shares via open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.